Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(14%)
Results Posted
11%(1 trials)

Phase Distribution

Ph phase_3
3
21%
Ph phase_4
6
43%
Ph phase_1
2
14%
Ph not_applicable
3
21%

Phase Distribution

2

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 3Large-scale testing
3(21.4%)
Phase 4Post-market surveillance
6(42.9%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(9)
Other(3)

Detailed Status

Completed9
unknown3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 33 (21.4%)
Phase 46 (42.9%)
N/A3 (21.4%)

Trials by Status

unknown321%
recruiting214%
completed964%

Recent Activity

2 active trials
Showing 5 of 14
recruitingphase_4

Aminoglycosides in Early Sepsis

NCT06712641
completednot_applicable

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

NCT05804123
unknownphase_4

Meropenem vs Cefotaxime as Empirical Treatment of SBP

NCT05427747
completednot_applicable

Impact of Cefotaxime and Ceftriaxone on the Emergence and Carrying of Multidrug-Resistant Bacteria

NCT03903783
completedphase_4

Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC

NCT01265173
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06712641Phase 4

Aminoglycosides in Early Sepsis

Recruiting
NCT05804123Not Applicable

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Completed
NCT05427747Phase 4

Meropenem vs Cefotaxime as Empirical Treatment of SBP

Unknown
NCT03903783Not Applicable

Impact of Cefotaxime and Ceftriaxone on the Emergence and Carrying of Multidrug-Resistant Bacteria

Completed
NCT01265173Phase 4

Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC

Completed
NCT04168099Phase 3

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

Recruiting
NCT02959957Phase 4

Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

Completed
NCT02659033Phase 3

Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.

Completed
NCT02443285Phase 3

Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?

Unknown
NCT02560207Phase 4

Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.

Completed
NCT01059890Phase 1

Cerebral Antibiotics Distribution After Acute Brain Injury

Completed
NCT02388035Not Applicable

Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis

Completed
NCT01820026Phase 4

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

Unknown
NCT00187655Phase 1

Effect of, OAT3, on the Renal Secretion of Cefotaxime

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14